Value
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 5.0 |
SRRK · Why this verdict
Why Scholar Rock Holding Corporatio (SRRK) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Scholar Rock is a single-asset biotech whose investment case rests entirely on the commercial trajectory of apitegromab; elevated short interest of 17% and consecutive earnings misses signal the market harbors deep skepticism that the company can reach profitability.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Despite the risks, analysts carry a consensus price target implying roughly 29% upside to current levels, providing a valuation cushion if the pipeline narrative remains intact. Sentiment breakdown | The stock reaches or approaches the analyst consensus target price, representing more than 16% gain from current levels, within 12 months. | →Stable |
| CounterAnalyst price targets for development-stage biotechs carry low reliability; targets are often revised down sharply following a clinical miss or cash raise. | ||
The company's entire revenue potential depends on a single drug candidate, apitegromab, making any clinical or regulatory setback immediately existential for the thesis. Bear case | Positive Phase 3 readout or regulatory filing progress for apitegromab within 12 months that reduces single-asset risk. | →Stable |
| CounterBiotech pipelines frequently encounter safety signals or efficacy shortfalls in late-stage trials, and a single-asset company has no fallback product to cushion a setback. | ||
Scholar Rock has missed EPS estimates in 3 of the last 4 quarters with an average negative surprise of 15.2%, suggesting its cash burn is running ahead of expectations. Earnings | Cash burn moderates such that at least 2 of the next 4 quarters come in at or above consensus EPS estimates. | →Stable |
| CounterPre-commercial biotechs routinely overshoot burn as they scale clinical and manufacturing operations, and the miss streak may reflect accelerating rather than controllable spending. | ||
A short interest of 17% and an extreme put-to-call ratio of 11.20 indicate that a large portion of the market is actively positioned against the stock, creating a significant supply overhang. Key risks | Short interest falls below 12% over 12 months as catalysts reduce bearish conviction. | →Stable |
| CounterElevated short interest in development-stage biotechs often reflects well-researched skepticism about clinical outcomes and can persist or grow if trial data disappoint. | ||
Despite the risks, analysts carry a consensus price target implying roughly 29% upside to current levels, providing a valuation cushion if the pipeline narrative remains intact.
→StableSentiment breakdown
- Expectation
- The stock reaches or approaches the analyst consensus target price, representing more than 16% gain from current levels, within 12 months.
CounterAnalyst price targets for development-stage biotechs carry low reliability; targets are often revised down sharply following a clinical miss or cash raise.
The company's entire revenue potential depends on a single drug candidate, apitegromab, making any clinical or regulatory setback immediately existential for the thesis.
→StableBear case
- Expectation
- Positive Phase 3 readout or regulatory filing progress for apitegromab within 12 months that reduces single-asset risk.
CounterBiotech pipelines frequently encounter safety signals or efficacy shortfalls in late-stage trials, and a single-asset company has no fallback product to cushion a setback.
Scholar Rock has missed EPS estimates in 3 of the last 4 quarters with an average negative surprise of 15.2%, suggesting its cash burn is running ahead of expectations.
→StableEarnings
- Expectation
- Cash burn moderates such that at least 2 of the next 4 quarters come in at or above consensus EPS estimates.
CounterPre-commercial biotechs routinely overshoot burn as they scale clinical and manufacturing operations, and the miss streak may reflect accelerating rather than controllable spending.
A short interest of 17% and an extreme put-to-call ratio of 11.20 indicate that a large portion of the market is actively positioned against the stock, creating a significant supply overhang.
→StableKey risks
- Expectation
- Short interest falls below 12% over 12 months as catalysts reduce bearish conviction.
CounterElevated short interest in development-stage biotechs often reflects well-researched skepticism about clinical outcomes and can persist or grow if trial data disappoint.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 75)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.7 |
| Price target | 6.6 |
| erm sentiment | 4.9 |
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $3,147,535 (0.050% of mkt cap)
Peer rank
2.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.3 |
| 52w position | 9.9 |
Risk (lower is worse)
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 0.0 |
| volatility | 2.1 |
| put call | 10.0 |
| implied vol | 2.8 |
| max pain risk | 7.0 |
| beta | 8.8 |
| debt equity | 6.5 |
- ▸High short interest justified: 17%
- ▸High IV: 63%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 7.0, Momentum at 6.6, and Value at 5.0; the weakest are Quality at 1.5, Catalyst at 2.5, and Peer rank at 2.5. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company's entire revenue potential depends on a single drug candidate, apitegromab, making any clinical or regulatory setback immediately existential for the thesis.
Trip ifStock price drops below $35, more than 24% below the current $45.92, on news of a clinical hold or material negative apitegromab data.
- P2Scholar Rock has missed EPS estimates in 3 of the last 4 quarters with an average negative surprise of 15.2%, suggesting its cash burn is running ahead of expectations.
Trip ifEPS surprise falls below -10% in at least 3 of the next 4 quarters, signaling cash burn is exceeding management guidance.
- P3A short interest of 17% and an extreme put-to-call ratio of 11.20 indicate that a large portion of the market is actively positioned against the stock, creating a significant supply overhang.
Trip ifShort interest rises above 20% of float, indicating bearish positioning is increasing beyond the current 17%.
- P4Despite the risks, analysts carry a consensus price target implying roughly 29% upside to current levels, providing a valuation cushion if the pipeline narrative remains intact.
Trip ifAnalyst consensus price target declines to below $48, less than 5% above current price, removing the valuation buffer.